Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of high-sulfation fucogalactan from brown algae in drugs and health care products for preventing and treating pulmonary fibrosis

A technology of sulfated fucoidan and galactan, applied in the field of medicine, can solve the problems of strong infectivity, public safety threat, and no specific drug treatment yet.

Pending Publication Date: 2021-09-03
INST OF OCEANOLOGY - CHINESE ACAD OF SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

COVID-19 is highly contagious and can cause a variety of serious complications, posing a great threat to global public safety
At present, most drugs such as baricitinib, remdesivir, chloroquine, etc. are still in clinical trials, and there is no specific drug treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of high-sulfation fucogalactan from brown algae in drugs and health care products for preventing and treating pulmonary fibrosis
  • Application of high-sulfation fucogalactan from brown algae in drugs and health care products for preventing and treating pulmonary fibrosis
  • Application of high-sulfation fucogalactan from brown algae in drugs and health care products for preventing and treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Preparation and chemical composition analysis of highly sulfated fucogalactan

[0018] (1) Remove silt from 5 kg of kelp, extract in a pressure cooker with water 20 times the weight of kelp for 3 hours, control the temperature at 100-105°C, and extract twice. Remove the algae, combine the two extracts, filter with diatomaceous earth, concentrate the filtrate, add 4 times the volume of the concentrate for precipitation, and filter to obtain crude polysaccharides. The yield of crude polysaccharides is 4.84%.

[0019] (2) Dissolving the crude polysaccharide in water to form a solution with a mass concentration of 1.5%, adding 2mol / L MgCl 2 Make MgCl 2 The final mass concentration is 0.05mol / L, add absolute ethanol at the same time, make the final weight concentration of ethanol be 20%, stir to generate precipitate, centrifuge to remove the precipitate, take supernatant and add 95% ethanol, make the final weight concentration of ethanol be 70-75% %, stirring to ...

Embodiment 2

[0028] Example 2: A fucoidan that prevents and treats pulmonary fibrosis alleviates lung EMT and TGF-β phenotypes in a BLM-induced mouse model

[0029] figure 2showed that a fucoidan that prevents pulmonary fibrosis attenuated lung EMT and TGF-β phenotypes in a BLM-induced mouse model. The fucoidan can down-regulate the PI3K-AKT pathway. On the one hand, the inhibition of the Akt pathway down-regulates β-catenin and COL2A1, which alleviates the occurrence of EMT and collagen accumulation. On the other hand, the fucoidan alleviated TGF-β can trigger inflammatory pathways.

Embodiment 3

[0030] Example 3: A fucoidan that prevents and treats pulmonary fibrosis alleviates the fibrosis state of A549 cells induced by TGF-β1

[0031] A549 cells were incubated with 10% fetal bovine serum and 5% CO 2 Cultivated in the 1640's. Cells were divided into 5×10 per well 4 Cells were seeded into 6-well plates at a density of 1×10 per well 4 Cell density was seeded into 24-well plates and 2000 cells per well into 96-well plates. After starvation in serum-free medium for 24 hours until reaching 60% confluency, they were treated with TGF-β1 (10 ng / mL), or co-treated with different concentrations of fucoidan (50, 100, 200 ug / mL) or TGF-β1 inhibitor (4 μM) was incubated for 36 hours for cell viability assays, scanning electron microscopy, morphological analysis and western blot analysis.

[0032] image 3 It was shown that a fucoidan that prevents pulmonary fibrosis can reduce the proliferation of A549 cells, increase the contact and connection between cells, and reduce the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of high-sulfation fucogalactan from brown algae in drugs and health care products for preventing and treating pulmonary fibrosis. The high-sulfation fucogalactan can significantly improve the degree of pulmonary fibrosis, inhibit excessive proliferation and activation of fibroblasts and reduce the deposition of extracellular matrix (ECM) of the lung. The high-sulfation fucogalactan is verified to be capable of lowering the PI3K-AKT pathway and reducing the expression of TGF-beta, beta-catenin and COL2A1 at the cellular and animal levels. The high-sulfation fucogalactan from brown algae can reduce the pulmonary fibrosis caused by damp-cold and damp-heat, inflammatory reactions, viral environments and inhalation of PM2.5, protect the lung structure integrity, reduce the pulmonary epithelial-mesenchymal transition (EMT) phenomenon and collagen deposition, and reduce the inflammatory reactions of the body. The high-sulfation fucogalactan from brown algae has wide application in drugs, health care products and food for preventing and treating pulmonary fibrosis-related symptoms / diseases.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of fucoidan, in particular to the application of highly sulfated fucogalactan in medicines and health care products for the prevention and treatment of pulmonary fibrosis. Background technique [0002] Novel coronavirus pneumonia (COVID-19) is caused by a new type of betacoronavirus-new coronavirus, which uses angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells and cause lung damage, exacerbation and secondary causes The systemic inflammatory response is closely related to acute respiratory distress syndrome and septic shock in critically ill patients and eventually to multiple organ failure. COVID-19 is highly contagious and can cause a variety of serious complications, posing a great threat to global public safety. At present, most drugs such as baricitinib, remdesivir, and chloroquine are still in the clinical trial stage, and there is no specific drug ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/737A61K36/03A61P11/00A23L33/125
CPCA61K31/737A61K36/03A61P11/00A23L33/125A23V2002/00A23V2250/51A23V2250/202A23V2200/314
Inventor 吴宁张全斌李志王晶耿丽华岳洋
Owner INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com